GLP1R and type 2 diabetes mellitus: Semaglutide is a glucagon-like peptide-1 receptor agonist that improves glycemic control and reduces cardiovascular outcomes in type 2 diabetes (T2D) by several mechanisms including enhanced β–cell response, postponed gastric emptying, inhibition of glucagon secretion, and weight-loss [1].